APVO - Aptevo Therapeutics Inc.

5.1
-0.110   -2.157%

Share volume: 19,119
Last Updated: 04-21-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$5.21
-0.11
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 33%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.41%
1 Month
13.59%
3 Months
-42.89%
6 Months
237.75%
1 Year
635.51%
2 Year
618.31%
Key data
Stock price
$5.10
P/E Ratio 
N/A
DAY RANGE
$5.00 - $5.52
EPS 
-$33.71
52 WEEK RANGE
$0.24 - $13.11
52 WEEK CHANGE
$589.19
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
1.182 M
DIVIDEND
$0.00
EX-DIVIDEND DATE
12-04-2024
NEXT EARNINGS DATE
05-07-2025
BETA 
2.22
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$25,753
AVERAGE 30 VOLUME 
$40,210
Company detail
CEO: Marvin L. White
Region: US
Website: aptevotherapeutics.com
Employees: 50
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aptevo Therapeutics Inc. focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company also has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.

Recent news